To reduce tumor growth and enhance treatment efficacy, therapies that disrupt this inflammatory and anti-apoptotic signaling pathway can target the hyperactivation of NF-κB, a characteristic of many cancers, including skin, colon, and breast cancers [53]. This evidence concerns the gene NFKB1 and breast cancer.